These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30569245)

  • 21. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.
    Xiao F; Zhang F; Zhang LL; Wei W
    Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8.
    Port A; Shaw JV; Klopp-Schulze L; Bytyqi A; Vetter C; Hussey E; Mammasse N; Ona V; Bachmann A; Strugala D; Reh C; Goteti K
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00842. PubMed ID: 34414672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.
    Leber A; Hontecillas R; Zoccoli-Rodriguez V; Colombel JF; Chauhan J; Ehrich M; Farinola N; Bassaganya-Riera J
    Inflamm Bowel Dis; 2020 Mar; 26(4):643-652. PubMed ID: 31077582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and biological evaluation of triazole-pyrimidine-methylbenzonitrile derivatives as dual A
    Li Z; Kou L; Fu X; Xie Z; Xu M; Guo L; Lin T; Gong S; Zhang S; Liu M
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1514-1526. PubMed ID: 35616298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Target Engagement in a First-in-Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders.
    Gehin M; Melchior M; Welford RWD; Sidharta PN; Dingemanse J
    Clin Transl Sci; 2021 Mar; 14(2):558-567. PubMed ID: 33142037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.
    Sjöberg F; Waters S; Löfberg B; Sonesson C; Waters N; Tedroff J
    Pharmacol Res Perspect; 2021 May; 9(3):e00792. PubMed ID: 34018344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A first-in-human study to evaluate the safety, tolerability and pharmacokinetics of RP3128, an oral calcium release-activated calcium (CRAC) channel modulator in healthy volunteers.
    Barde PJ; Viswanadha S; Veeraraghavan S; Vakkalanka SV; Nair A
    J Clin Pharm Ther; 2021 Jun; 46(3):677-687. PubMed ID: 33314326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
    J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.
    Muehlan C; Brooks S; Zuiker R; van Gerven J; Dingemanse J
    Eur Neuropsychopharmacol; 2019 Jul; 29(7):847-857. PubMed ID: 31221502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects.
    Sunwoo J; Oh J; Moon SJ; Ji SC; Lee SH; Yu KS; Kim HS; Lee A; Jang IJ
    Aliment Pharmacol Ther; 2018 Jul; 48(2):206-218. PubMed ID: 29863280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
    Yang H; Merica E; Chen Y; Cohen M; Goldwater R; Kosinski PA; Kung C; Yuan ZJ; Silverman L; Goldwasser M; Silver BA; Agresta S; Barbier AJ
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):246-259. PubMed ID: 30091852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers.
    Wallace M; White A; Grako KA; Lane R; Cato AJ; Snodgrass HR
    Scand J Pain; 2017 Oct; 17():243-251. PubMed ID: 29229209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
    Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
    J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
    J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers.
    Kankam MK; Burns JM; Collett MS; Corrado ML; Hincks JR
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0102921. PubMed ID: 34370575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.